MEDBOT-B (02252) announced the appointment of Dr. Chang Zhaohua, Mr. Shirafuji Taishi, Mr. Ashida Norihiro, and Ms. Liang Min as non-executive directors, effective upon the conclusion of the extraordinary general meeting. Additionally, Dr. Liu Guoen and Mr. Zhou Jiahong have been appointed as independent non-executive directors, also effective from the same date. Dr. Chang Zhaohua has been further appointed as Chairman of the Board, effective November 25, 2025.
The Board also announced changes to its committee compositions effective November 25, 2025: - The Audit Committee will comprise independent non-executive director Mr. Zhou Jiahong, Mr. Zhong Weiwen, and non-executive director Mr. Ashida Norihiro, with Mr. Zhou Jiahong serving as Chairman. - The Remuneration and Appraisal Committee will include independent non-executive director Dr. Liu Guoen, Mr. Zhou Jiahong, and non-executive director Mr. Ashida Norihiro, chaired by Dr. Liu Guoen. - The Nomination Committee will consist of independent non-executive director Mr. Yao Haisong, Mr. Zhong Weiwen, and non-executive director Ms. Liang Min, with Mr. Yao Haisong as Chairman. - The Strategy and Development Committee will be composed of independent non-executive director Dr. Liu Guoen, non-executive director Mr. Shirafuji Taishi, and executive director Dr. He Chao, chaired by Dr. Liu Guoen. - The Commercialization Committee will include non-executive director Mr. Shirafuji Taishi, Mr. Chen Chen, executive director Mr. Liu Yu, and non-executive director Ms. Liang Min, with Mr. Shirafuji Taishi as Chairman.
Furthermore, the Board announced that Mr. Sun Hongbin will no longer serve as the company’s authorized representative under Listing Rule 3.05. Dr. Chang Zhaohua will succeed Mr. Sun in this role, effective November 25, 2025.
Comments